Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Total Debt

Short-term and long-term borrowings combined.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 20.1% from a year ago

Total debt stood at $1.99M at the end of Q1 FY2026, down 20.1% from a year earlier and down 6.2% from the prior quarter. Over 3 fiscal years it compounded at +45.7% a year.

Context

  • Total debt amounted to 1.0% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -20.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.99M-6.2% QoQ
Last fiscal yearDec 2025
$2.12M— YoY
Year agoMar 2025
$2.48M-20.1% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.1%——
1 year———
3-year CAGR+45.7%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
2.12M USD
Year-over-year change
—
4-year CAGR
+32.2%

Total Debt vs competitors

How ACRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -20.1% is the 6th highest of 7, against a peer median of +8.5%.
  • Total debt amounts to 1.0% of total assets for ACRS, versus a peer median of 3.4%.
ACRS Competitors
Total Debt for ACRS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANABAnaptysBio, Inc.Mar 2026$277.36M USD+1680.8%-10.1%84.1%
MLTXMoonLake ImmunotherapeuticsMar 2026$100.8M USD+33.3%+544.7%25.2%
ALMSAlumis Inc. Common StockJun 2026$36.43M USD-6.1%+174.8%6.5%
ALDXAldeyra Therapeutics, Inc.Mar 2026$15.51M USD-0.3%-1.2%23.3%
ATTOAttovia Therapeutics, Inc.Jun 2026$4.33M USD——3.4%
ACRSAclaris Therapeutics, Inc.Mar 2026$1.99M USD-20.1%+45.7%1.0%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€1.33M EUR——0.8%
IFRXInflaRx N.V.Mar 2026€823.89K EUR+17.3%-12.9%1.7%
IMUXImmunic, Inc.Mar 2026$421K USD-56.8%-24.1%0.2%
TRAXFirst Tracks Biotherapeutics IncMar 2026$0 USD——0.0%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ACRS) —+8.5%-5.7%3.4%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.35M45.28M39.88M24.57M19.96M
Short-term Investments164.07M172.29M79.23M89.02M70.79M
Net Receivables623K484K298K318K5.57M
Inventory00000
Other Current Assets013.5M9.45M12.04M55.05M
Total Current Assets205.03M231.55M128.86M125.95M151.36M
Property, Plant & Equipment (Net)1.34M1.1M1.62M1.01M0
Goodwill00000
Intangible Assets7.05M6.97M269K00
Long-term Investments34.24M12.24M62.77M90.3M60.61M
Tax Assets00000
Other Non-current Assets3.55M2.73M3.89M3.07M(51.52M)
Total Non-current Assets46.18M23.05M68.55M94.38M9.1M
Total Assets251.21M254.6M197.41M220.33M160.46M
Account Payables9.99M10.35M8.88M4.69M13.16M
Short-term Debt0000551K
Tax Payables00000
Deferred Revenue0003.89M3.94M
Other Current Liabilities6.59M7.5M6.11M11.59M5.7M
Total Current Liabilities22.93M21.94M30.95M31.6M28.65M
Long-term Debt00000
Deferred Tax Liabilities367K367K000
Deferred Revenue (Non-current)00020.04M16.17M
Other Non-current Liabilities30.57M34.67M9.27M13.14M11M
Total Non-current Liabilities30.94M35.04M9.27M33.18M28.73M
Total Liabilities53.87M56.98M40.23M64.77M57.38M
Common Stock1K1K1K1K1K
Retained Earnings(595.41M)(682.32M)(770.8M)(902.86M)(967.78M)
Accumulated OCI(224K)(897K)(106K)97K610K
Other Stockholders Equity00000
Minority Interest00000
Total Equity197.34M197.62M157.18M155.55M103.08M
Total Debt693K684K426K02.12M
Net Debt(26.66M)(44.59M)(39.45M)(24.57M)(17.84M)

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.